Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15295184 | 0.86 | KDM6B (0.72) | NAMPTKDM4ESMN1; SMN2HSD17B10TSHR | |
| SCHEMBL7632830 | 0.82 | KDM4E (0.72) | KDM4ESMN1; SMN2HSD17B10TSHRMAPK10 | |
| SCHEMBL20379211 | 0.81 | ALDH1A1 (0.80) | NAMPTKDM4ESMN1; SMN2HSD17B10TSHR | |
| SCHEMBL10501732 | 0.80 | KDM4E (0.78) | KDM4ESMN1; SMN2HSD17B10TSHRMAPK10 | |
| SCHEMBL6014596 | 0.80 | ADRA1D (0.61) | NAMPTKDM4EHSD17B10TSHRMAPK10 | |
| SCHEMBL4863213 | 0.79 | KDM4E (0.68) | KDM4ESMN1; SMN2HSD17B10TSHRMAPK10 | |
| SCHEMBL4861758 | 0.79 | SMN1; SMN2 (0.72) | KDM4ESMN1; SMN2HSD17B10TSHRMAPK10 | |
| SCHEMBL15286181 | 0.79 | KDM6B (0.73) | NAMPTKDM4ESMN1; SMN2HSD17B10TSHR | |
| SCHEMBL14085807 | 0.79 | KDM4E (0.76) | KDM4ESMN1; SMN2HSD17B10TSHRMAPK10 | |
| SCHEMBL28723675 | 0.78 | ALDH1A1 (0.54) | KDM4ESMN1; SMN2HSD17B10TSHRMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633712-B1 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | CHEN GUOQING PAUL (US) | 2014-06-25 | — | — | EP | disclosed |
| US-7129252-B2 | Six membered amino-amide derivatives an angiogenisis inhibitors | HLB CO., LTD. (KR) | 2006-10-31 | — | — | US | disclosed |
| EP-1633712-A2 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Chen, Guoqing Paul (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005000232-A2 | SIX MEMBERED AMINO-AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | CHEN GUOQING PAUL (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040259916-A1 | Six membered amino-amide derivatives an angiogenisis inhibitors | HLB CO., LTD. (KR) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259916-A1 | Six membered amino-amide derivatives an angiogenisis inhibitors | TEK, FLT1, VEGFA | NAMPT 255/4885KDM4E 1427/4885SMN1; SMN2 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.